American Journal of Ophthalmology
Volume 141, Issue 6 , Pages 1061-1067.e1 , June 2006

Progression of Visual Field Defects in Leber Hereditary Optic Neuropathy: Experience of the LHON Treatment Trial

  • Nancy J. Newman, MD

      Affiliations

    • Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
    • Department of Neurology, Emory University School of Medicine, Atlanta, Georgia
    • Department of Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia
    • Corresponding Author InformationInquiries to Nancy J. Newman, MD, Neuro-Ophthalmology Unit, Emory Eye Center, 1365-B Clifton Road NE, Atlanta, GA 30322
    • ,
  • Valérie Biousse, MD

      Affiliations

    • Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia
    • Department of Neurology, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Steven A. Newman, MD

      Affiliations

    • Department of Ophthalmology, University of Virginia, Charlottesville, Virginia
    • ,
  • M. Tariq Bhatti, MD

      Affiliations

    • Departments of Ophthalmology, Neurology, and Neurosurgery, University of Florida, Gainesville, Florida
    • ,
  • Steven R. Hamilton, MD

      Affiliations

    • Swedish Neuroscience Institute, Seattle, Washington
    • ,
  • Bradley K. Farris, MD

      Affiliations

    • Dean A. McGee Eye Institute, Oklahoma City, Oklahoma
    • ,
  • Robert L. Lesser, MD

      Affiliations

    • Departments of Ophthalmology and Visual Science and Neurology, Yale University School of Medicine, New Haven, Connecticut
    • ,
  • Roger E. Turbin, MD

      Affiliations

    • Institute of Ophthalmology and Visual Sciences, University of Medicine and Dentistry of New Jersey, Newark, New Jersey

,Accepted 22 December 2005.

References 

  1. Van Senus AHC . Leber’s disease in The Netherlands . Doc Ophthalmol . 1963;17:1–163
  2. Newman NJ , Lott MT , Wallace DC . The clinical characteristics of pedigrees of Leber’s hereditary optic neuropathy with the 11778 mutation . Am J Ophthalmol . 1991;111:750–762
  3. Riordan-Eva P , Sanders MD , Govan GG , et al.   The clinical features of Leber’s hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation . Brain . 1995;118:319–337
  4. Newman NJ , Biousse V , David R , et al.   Prophylaxis for second eye involvement in Leber’s hereditary optic neuropathy (an open-labeled, nonrandomized multicenter trial of topical brimonidine purite) . Am J Ophthalmol . 2005;140:407–411
  5. Carrol WM , Mastaglia FL . Leber’s optic neuropathy (a clinical and visual evoked potential study of affected and asymptomatic members of a six generation family) . Brain . 1979;102:559–580
  6. Stehouwer A , Went LN . Leber’s optic neuropathy I (clinical studies) . Doc Ophthalmol . 1982;53:97–111
  7. Miller NR . In: 4th ed.. Walsh and Hoyt’s clinical neuro-ophthalmology . Vol 1: Baltimore: Williams & Wilkins; 1982;p. 312–314
  8. Nikoskelainen EK , Huoponen K , Juvonen V , et al.   Ophthalmologic findings in Leber’s hereditary optic neuropathy, with special reference to mtDNA mutation . Ophthalmology . 1996;103:504–514
  9. Sadun F , De Negri AM , Carelli V , et al.   Ophthalmologic findings in a large pedigree of 11778/haplogroup J Leber’s hereditary optic neuropathy . Am J Ophthalmol . 2004;137:271–277
  10. Nikoskelainen E , Hoyt WF , Nummelin K . Ophthalmoscopic findings in Leber’s hereditary optic neuropathy. II. The fundus findings in the affected family members . Arch Ophthalmol . 1983;101:1059–1068
  11. Nikoskelainen E , Sogg RL , Rosenthal AR , et al.   The early phase in Leber’s hereditary optic atrophy . Arch Ophthalmol . 1977;95:969–978
  12. Dorfman LJ , Nikoskelainen E , Rosenthal AR , Sogg RL . Visual evoked potentials in Leber’s hereditary optic neuropathy . Ann Neurol . 1977;1:565–568
  13. Livingstone IR , Mastaglia FL , Howe JW , Aherne GES . Leber’s optic neuropathy (clinical and visual evoked response studies in asymptomatic and symptomatic members of a 4-generation family) . Br J Ophthalmol . 1980;64:751–757
  14. Mondelli M , Rossi A , Scarpini C , Dotti MT , Federico A . Leber’s optic atrophy (VEP and BAEP changes in 16 asymptomatic subjects) . Acta Neurol Scand . 1991;84:366
  15. Rönne H . Über das Gesichtsfeld bei hereditarer Opticusatropfie (Leber) . Klin Monatsbl Augenheilkd . 1910;48:331–333
  16. Traquair HM . In: An introduction to clinical perimetry . St Louis: CV Mosby; 1927;p. 151–153
  17. Asseman R . In: La maladie de Leber (étude clinique et génétique á propos de 86 cas examinés) . Université de Lille; 1958;p. 1–148 [MD thesis]
  18. Bell J . Hereditary optic atrophy (Leber’s disease) . In:  Pearson K editors. The treasury of human inheritance . London: Cambridge University Press; 1931;p. 336–337
  19. Bird A , McEachern D . Leber’s hereditary optic atrophy in a Canadian family . Can Med Assoc J . 1949;61:376–383
  20. Raaf JE , Bair HL . Leber’s disease (report of four cases in one family) . Am J Ophthalmol . 1938;21:384–389
  21. Weiner NC , Newman NJ , Lessell S , et al.   Atypical Leber’s hereditary optic neuropathy with molecular confirmation . Arch Neurol . 1993;50:470–473
  22. Phillips PH , Vaphiades M , Glasier CM , et al.   Chiasmal enlargement and optic nerve enhancement on magnetic resonance imaging in Leber’s hereditary optic neuropathy . Arch Ophthalmol . 2003;121: 577–570
  23. Vaphiades MS , Phillips Ph , Turbin RE . Optic nerve and chiasmal enhancement in Leber’s hereditary optic neuropathy . J Neuroophthalmol . 2003;23:104–105
  24. Batioglu F , Atilla H , Eryilmaz T . Chiasmal high signal on magnetic resonance imaging in the atrophic phase of Leber’s hereditary optic neuropathy . J Neuroophthalmol . 2003;23:28–30
  25. Votruba M , Fitzke FW , Holder GE , et al.   Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy . Arch Ophthalmol . 1998;116:351–358
  26. Sadun AA , Win P , Ross-Cisneros F , et al.   Leber’s hereditary optic neuropathy differentially affects smaller axons in the optic nerve . Trans Am Ophthalmol Soc . 2000;98:1–13

 N.J.N. acted as a consultant for Allergan Inc.Supported in part by Allergan Inc, Irvine, California. N.J.N. and V.B. were supported in part by a departmental grant (Department of Ophthalmology) from Research to Prevent Blindness Inc, New York, New York, and by core grant P30-EY06360 (Department of Ophthalmology) from the National Institutes of Health, Bethesda, Maryland. N.J.N. is a recipient of a Research to Prevent Blindness Lew R. Wasserman Merit Award. R.E.T.’s work was supported by the Gene C. Coppa Memorial Fund.

PII: S0002-9394(06)00018-3

doi: 10.1016/j.ajo.2005.12.045

American Journal of Ophthalmology
Volume 141, Issue 6 , Pages 1061-1067.e1 , June 2006

Article Tools

* Image Usage & Resolution